Olivia Esposito • February 5, 2024
Yale New Haven Hospital Heart and Vascular Center – New Haven, CT

Yale New Haven Hospital Heart and Vascular Center offer multidisciplinary services from the latest imaging techniques and genetic profiling of HCM to advanced diagnostic testing, treatment options, and clinical trials – all with an emphasis on compassion and communication.

Yale New Haven’s well-established HCM center provides specialized, expert physicians and staff specially trained to manage HCM. This multidisciplinary team has the experience necessary to provide seamless care to patients and their families at every age and stage of this disease. Yale has three Co-Directors of the HCM Program: Dr. Rachel Lampert, Dr. John Stendahl, and Dr. Sounok Sen.

The HCM team includes specialists in:

  • Adult and Pediatric Cardiology
  • Advanced Heart Failure Cardiology
  • CardiacaAesthesia
  • Cardiac Electrophysiology
  • Cardiac Genetics
  • Cardiac Imaging
  • Cardiac Surgery
  • Cardio-Obstetrics
  • Interventional Cardiology
  • Nutrition
  • Research
  • Social Work

Services include medical management, genetic counseling, family screening, advanced management of heart rhythm disorders, catheter-based procedures, and surgical interventions when necessary. Yale New Haven HCM Team provides clinical trial access and monthly support group meetings.

The Yale New Haven HCM Team recently participated in our BigHearted Warriors Unite Webinar Series. If you would like to watch team members Dr. Rachel Lampert, Dr. John Stendahl,  Dr. Sounok Sen, Dr.Arya Mani, and Dr. Nikhil Sikand’s free Bighearted Warriors education webinar, please visit  https://www.youtube.com/live/xXvmdTJNxKQ?si=oFRIw70lYUmM-FL6.

For more information on the Yale New Haven HCM Program in New Haven, CT, please visit:  https://4hcm.org/yale/


For more information on all HCMA-recognized centers of excellence, please visit  https://4hcm.org/center-of-excellence/.

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts